Chemotherapy Induced Acral Erythema Treatment Market

Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear after several months of treatment with chemotherapeutic agents, gemcitabine and fluorouracil being the most common drugs causing reaction. Chemotherapy induced acryl erythema is a dose dependent condition, regression of which can be achieved by discontinuation of chemotherapy or by dose reduction. Treatment for chemotherapy induced acryl erythema includes symptomatic treatment with analgesics and antihistaminic drugs to reduce pain and edema.
Chemotherapy Induced Acral Erythema Treatment Market contains market size and forecasts of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment in Global, including the following market information:
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Analgesics Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment include Taro, Oceanside Pharmaceuticals, Pfizer, Novartis, A-S Medication Solutions, Preferred Pharmaceuticals, Syntex Pharmaceuticals, Valeant Canada and Technilab Pharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Segment Percentages, by Type, 2021 (%)
Analgesics
Anti-Inflammatory And Anti-Edematous Agents
Antihistaminic
NSAIDs
Oral/Topical Glucocorticoids
Pyridoxine (Vitamin B6)
Others
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Segment Percentages, by Application, 2021 (%)
Pharmacy And Drugstores
Hospital Pharmacy
Online Drug Stores
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Taro
Oceanside Pharmaceuticals
Pfizer
Novartis
A-S Medication Solutions
Preferred Pharmaceuticals
Syntex Pharmaceuticals
Valeant Canada
Technilab Pharma
Allergan